Patient Square Capital LP Astria Therapeutics, Inc. Transaction History
Patient Square Capital LP
- $267 Billion
- Q4 2024
A detailed history of Patient Square Capital LP transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Patient Square Capital LP holds 105,057 shares of ATXS stock, worth $687,072. This represents 0.35% of its overall portfolio holdings.
Number of Shares
105,057
Previous 39,422
166.49%
Holding current value
$687,072
Previous $434 Million
116.39%
% of portfolio
0.35%
Previous 0.16%
Shares
2 transactions
Others Institutions Holding ATXS
# of Institutions
115Shares Held
50.3MCall Options Held
75KPut Options Held
6.2K-
Perceptive Advisors LLC New York, NY6.49MShares$42.4 Million1.91% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.11MShares$33.4 Million0.73% of portfolio
-
Vestal Point Capital, LP New York, NY4.18MShares$27.3 Million2.22% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.55MShares$23.2 Million6.29% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$23 Million0.0% of portfolio
About Astria Therapeutics, Inc.
- Ticker ATXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,178,000
- Market Cap $99.3M
- Description
- Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...